Serum phosphorylated tau 217 in GBA1 variant carriers with and without Parkinson disease

Authors:

Abstract
It is unclear whether Alzheimer disease pathology drives cognitive decline in Parkinson disease (PD) patients carrying GBA1 variants. We evaluated levels of serum phosphorylated tau 217 (p-tau217) in samples from 29 GBA1 -PD, 32 idiopathic PD, 20 non-manifesting GBA1 variant carriers ( GBA1 -NMC) and 31 healthy controls. No differences were detected between PD groups. GBA1 -NMCs showed higher levels than healthy controls, which correlated to worse cognition and subthreshold parkinsonism. Serum p-tau217 is not a marker of cognitive decline in GBA1 -PD. Whether p-tau217 levels in GBA1 -NMCs can predict conversion to PD or are a marker of cognitive decline, irrespective of PD, remains unknown.

This publication has 34 references indexed in Scilit: